Augmedix, Inc. (NASDAQ:AUGX) Short Interest Update

Augmedix, Inc. (NASDAQ:AUGX) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 831,500 shares, a growth of 11.2% from the March 15th total of 748,000 shares. Based on an average daily trading volume, of 377,800 shares, the days-to-cover ratio is currently 2.2 days. Currently, 1.9% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AUGX. Evercore ISI upgraded Augmedix from an “in-line” rating to an “outperform” rating and increased their price target for the company from $4.50 to $5.00 in a research report on Tuesday, April 9th. B. Riley began coverage on Augmedix in a research report on Wednesday, April 3rd. They issued a “buy” rating and a $5.50 price target for the company. Finally, Maxim Group decreased their price target on Augmedix from $6.50 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, March 19th.

Augmedix Price Performance

Shares of NASDAQ:AUGX traded down $0.33 during midday trading on Tuesday, reaching $3.43. The company had a trading volume of 177,753 shares, compared to its average volume of 374,938. The company has a current ratio of 2.41, a quick ratio of 2.41 and a debt-to-equity ratio of 0.66. Augmedix has a 1-year low of $1.56 and a 1-year high of $6.25. The company has a fifty day simple moving average of $4.12 and a two-hundred day simple moving average of $4.82.

Augmedix (NASDAQ:AUGX) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $12.68 million during the quarter, compared to analysts’ expectations of $12.30 million. Augmedix had a negative return on equity of 308.50% and a negative net margin of 42.74%. Research analysts forecast that Augmedix will post -0.51 earnings per share for the current year.

Insider Activity at Augmedix

In related news, insider Ian Shakil sold 58,978 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $3.91, for a total transaction of $230,603.98. Following the completion of the transaction, the insider now owns 180,034 shares of the company’s stock, valued at $703,932.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 250,823 shares of company stock valued at $1,003,627 over the last 90 days. 10.97% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Augmedix

Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in Augmedix in the 3rd quarter worth about $48,000. Symmetry Peak Management LLC purchased a new stake in Augmedix in the 4th quarter worth about $88,000. Worth Venture Partners LLC purchased a new stake in shares of Augmedix during the 3rd quarter worth about $83,000. Thompson Davis & CO. Inc. purchased a new stake in shares of Augmedix during the 4th quarter worth about $120,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Augmedix during the 4th quarter worth about $122,000. 87.11% of the stock is owned by hedge funds and other institutional investors.

Augmedix Company Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.